COVID-19 vaccination challenges: A mini-review

References

• Sadeghi-Haddad-Zavareh M, Bayani M, Shokri M , Ebrahimpour, S, Babazadeh A, Mehraeen R, Moudi E, Rostami A, Barary M, Hosseini A, et al. C-Reactive protein as a prognostic indicator in COVID-19 patients. Interdiscip Perspect Infect Dis. 2021;2021:5557582. doi:10.1155/2021/5557582.
   PubMedGoogle Scholar
• Javanian M, Bayani M, Shokri M, Sadeghi-Haddad-Zavareh M, Babazadeh A, Ghadimi R, Sepidarkish M, Bijani A, Yahyapour Y, Barary M, et al. Risk factors for mortality of 557 adult patients with COVID 19 in Babol, Northern Iran: a retrospective cohort study. Bratisl Lek Listy. 2021;122:34–9. doi:10.4149/BLL_2021_003.
   PubMed Web of Science ®Google Scholar
• Miladi R, Janbakhsh A, Babazadeh A, Aryanian Z, Ebrahimpour S, Barary M, Sio TT, Wollina U, Goldust M, Mohseni Afshar Z. Pustular psoriasis flare-up in a patient with COVID-19. J Cosmet Dermatol. 2021;20(11):3364–3368. doi:10.1111/jocd.14508.
   PubMed Web of Science ®Google Scholar
• Tregoning JS, Brown ES, Cheeseman HM, Flight KE, Higham SL, Lemm NM, Pierce BF, Stirling DC, Wang Z, Pollock KM, et al. Vaccines for COVID-19. Clin Exp Immunol. 2020;202:162–92. doi:10.1111/cei.13517.
   PubMed Web of Science ®Google Scholar
• Bollyky TJ, Gostin LO, Hamburg MA. The equitable distribution of COVID-19 therapeutics and vaccines. Jama. 2020;323:2462–63. doi:10.1001/jama.2020.6641.
   PubMed Web of Science ®Google Scholar
• Mascola JR, Fauci AS. Novel vaccine technologies for the 21st century. Nat Rev Immunol. 2020;20:87–88. doi:10.1038/s41577-019-0243-3.
   PubMed Web of Science ®Google Scholar
• Peiris M, Leung GM. What can we expect from first-generation COVID-19 vaccines? Lancet. 2020;396:1467. doi:10.1016/S0140-6736(20)31976-0.
   PubMed Web of Science ®Google Scholar
• Sharma K, Koirala A, Nicolopoulos K, Chiu C, Wood N, Britton PN. Vaccines for COVID-19: Where do we stand in 2021? Paediatr Respir Rev. 2021;39:22–31. doi:10.1016/j.prrv.2021.07.001.
   PubMed Web of Science ®Google Scholar
• Cobey S, Larremore DB, Grad YH, Lipsitch M. Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination. Nat Rev Immunol. 2021;1–6. doi:10.1038/s41577-020-00486-8.
   PubMed Web of Science ®Google Scholar
• Zhang M, Liang Y, Yu D, Du B, Cheng W, Li L, Yu Z, Luo S, Zhang Y, Wang H, et al. A systematic review of vaccine breakthrough infections by SARS-CoV-2 delta variant. Int J Biol Sci. 2022;18:889–900. doi:10.7150/ijbs.68973.
   PubMed Web of Science ®Google Scholar
• Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, Schaefer-Babajew DJ, DaSilva J, Muecksch F, Gaebler C, et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med. 2021;384:2212–18. doi:10.1056/NEJMoa2105000.
   PubMed Web of Science ®Google Scholar
• Geysels D, Van Damme P, Verstrepen W, Bruynseels P, Janssens B, Smits P, Naesens R. SARS-CoV-2 vaccine breakthrough infections among healthcare workers in a large Belgian hospital network. Infect Control Hosp Epidemiol. 2021;1–2. doi:10.1017/ice.2021.326.
   PubMedGoogle Scholar
• Brinkley-Rubinstein L, Peterson M, Martin R, Chan P, Berk J. Breakthrough SARS-CoV-2 infections in prison after vaccination. N Engl J Med. 2021;385:1051–52. doi:10.1056/NEJMc2108479.
   PubMed Web of Science ®Google Scholar
• Noor R. Developmental status of the potential vaccines for the mitigation of the COVID-19 pandemic and a focus on the effectiveness of the Pfizer-BioNtech and Moderna mRNA vaccines. Curr Clin Microbiol Rep. 2021;8:178–85. doi:10.1007/s40588-021-00162-y.
   PubMed Web of Science ®Google Scholar
• Noor R. Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic. Tzu-Chi Med J. 2021;33:7. doi:10.4103/tcmj.tcmj_100_20.
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, Lam EC, Denis KS, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv 2021: 2021.02.14.21251704.
   Google Scholar
• Dos Santos WG. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines. Biomed Pharmacother. 2021;136:111272. doi:10.1016/j.biopha.2021.111272.
   PubMed Web of Science ®Google Scholar
• Sathian B, Asim M, Banerjee I, Roy B, Pizarro AB, Mancha MA, Teijlingen ERV, Varkaneh HK, Mekkodathil AA, Subramanya SH, et al. Development and implementation of a potential coronavirus disease 2019 (COVID-19) vaccine: a systematic review and meta-analysis of vaccine clinical trials. Nepal J Epidemiol. 2021;11:959. doi:10.3126/nje.v11i1.36163.
   PubMed Web of Science ®Google Scholar
• Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, Turner RJ. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines. 2021;9:467. doi:10.3390/vaccines9050467.
   PubMed Web of Science ®Google Scholar
• Ling Y, Zhong J, Luo J. Safety and effectiveness of SARS‐CoV‐2 vaccines: a systematic review and meta‐analysis. J Med Virol. 2021;93:6486–95. doi:10.1002/jmv.27203.
   PubMed Web of Science ®Google Scholar
• Yuan P, Ai P, Liu Y, Ai Z, Wang Y, Cao W, et al. Safety, tolerability, and immunogenicity of COVID-19 vaccines: a systematic review and meta-analysis. MedRxiv. 2020.
   Google Scholar
• Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty. 2021;10:132. doi:10.1186/s40249-021-00915-3.
   PubMed Web of Science ®Google Scholar
• Cascella M, Rajnik M, Aleem A, Dulebohn S, Di Napoli R Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls. 2022.
   Google Scholar
• Abu-Raddad L, Chemaitelly H, Ayoub H, Coyle P, Malek J, Ahmed A. Introduction and expansion of the SARS-CoV-2 B. 1.1. 7 variant and reinfectionsAU: In the title; changeditsreinfectionstojustreinfectionsforidiomaticreasons: But if you feel that the its is important for meaning; pleasereinstateit: in Qatar: a nationally representative cohort study. PLoS Med. 2021;18:e1003879. doi:10.1371/journal.pmed.1003879.
   PubMedGoogle Scholar
• Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385:585–94. doi:10.1056/NEJMoa2108891.
   PubMed Web of Science ®Google Scholar
• Pawlowski C, Lenehan P, Puranik A, Agarwal V, Venkatakrishnan A, Niesen MJ, O’-Horo JC, Virk A, Swift MD, Badley AD, et al. FDA-Authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Med. 2021;2:979–92. e8. doi:10.1016/j.medj.2021.06.007.
   PubMedGoogle Scholar
• Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, Pizarro A, Acevedo J, Leo K, Leon F, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385:875–84. doi:10.1056/NEJMoa2107715.
   PubMed Web of Science ®Google Scholar
• Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo-Sanmartín C, Burgui C, et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Eurosurveillance. 2021;26:2100438.
   Web of Science ®Google Scholar
• Kadire SR, Wachter RM, Lurie N. Delayed second dose versus standard regimen for Covid-19 vaccination. N Engl J Med. 2021;3584:e28. doi:10.1056/NEJMclde2101987.
   Google Scholar
• Iacobucci G, Mahase E. Covid-19 vaccination: What’s the evidence for extending the dosing interval? Bmj. 2021;372:n18. doi:10.1136/bmj.n18.
   PubMedGoogle Scholar
• Mahase E. Covid-19: Medical community split over vaccine interval policy as WHO recommends six weeks. Bmj. 2021;372:n226. doi:10.1136/bmj.n226.
   PubMedGoogle Scholar
• WH Organization. Technical note on delayed shipments for the ChAdox1-S [recombinant] vaccines: what are the implications for the administration of second doses? scientific brief, May 26 2021. World Health Organization; 2021.
   Google Scholar
• Wang X, Du Z, Johnson KE, Pasco RF, Fox SJ, Lachmann M, et al. The impacts of COVID-19 vaccine timing, number of doses, and risk prioritization on mortality in the US. medRxiv2021.
   Google Scholar
• Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nature Human Behaviour. 2021;1–7.
   PubMed Web of Science ®Google Scholar
• Engelbrecht FA, Scholes RJ. Test for Covid-19 seasonality and the risk of second waves. One Health. 2021;12:100202. doi:10.1016/j.onehlt.2020.100202.
   PubMed Web of Science ®Google Scholar
• Soleimanpour S, Yaghoubi A. COVID-19 vaccine: where are we now and where should we go? Expert Rev Vaccines. 2021;20:23–44. doi:10.1080/14760584.2021.1875824.
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, et al. Safety and immunogenicity of the ChAdox1 nCov-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–78. doi:10.1016/S0140-6736(20)31604-4.
   PubMed Web of Science ®Google Scholar
• Graham SP, McLean RK, Spencer AJ, Belij-Rammerstorfer S, Wright D, Ulaszewska M, Edwards JC, Hayes JWP, Martini V, Thakur N, et al. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdox1 nCov-19. Npj Vaccines. 2020;5(1):1–6. doi:10.1038/s41541-020-00221-3.
   PubMed Web of Science ®Google Scholar
• Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. The Lancet. 2021;397:642–43. doi:10.1016/S0140-6736(21)00191-4.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng’-Ang’a D, Brandariz KL, Abbink P, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine. 2011;29:5203–09. doi:10.1016/j.vaccine.2011.05.025.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, et al. Interim results of a Phase 1–2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021;384:1824–35. doi:10.1056/NEJMoa2034201.
   PubMed Web of Science ®Google Scholar
• Syomin B, Ilyin Y. Virus-Like particles as an instrument of vaccine production. Mol Biol. 2019;53:323–34. doi:10.1134/S0026893319030154.
   PubMed Web of Science ®Google Scholar
• Tian J-H, Patel N, Haupt R, Zhou H, Weston S, Hammond H, Logue J, Portnoff AD, Norton J, Guebre-Xabier M, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021;12:1–14. doi:10.1038/s41467-020-20653-8.
   PubMed Web of Science ®Google Scholar
• Duggal N, Mohapatra C, Kumar R. Vaccine and therapeutics for COVID-19: an overview.
   Google Scholar
• van Riel D, de Wit E. Next-Generation vaccine platforms for COVID-19. Nat Mater. 2020;19:810–12. doi:10.1038/s41563-020-0746-0.
   PubMed Web of Science ®Google Scholar
• Samaranayake LP, Seneviratne CJ, Fakhruddin KS Coronavirus disease 2019 (COVID-19) vaccines: a concise review. Oral Dis 2021.
   Google Scholar
• McAndrew TC, Cambeiro J, Besiroglu T Aggregating probabilistic predictions of the safety, efficacy, and timing of a COVID-19 vaccine. medRxiv 2021.
   Google Scholar
• Mahase E. Covid-19: UK approves Moderna vaccine to be given as two doses 28 days apart. Bmj. 2021;372:n74. doi:10.1136/bmj.n74.
   PubMed Web of Science ®Google Scholar
• Doroftei B, Ciobica A, Ilie OD, Maftei R, Ilea C. Mini-Review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics (Basel). 2021;11:579. doi:10.3390/diagnostics11040579.
   PubMedGoogle Scholar
• Sacks HS. The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at≥ 14 d. Ann Intern Med. 2021;174:JC75. doi:10.7326/ACPJ202107200-075.
   PubMed Web of Science ®Google Scholar
• Therapeutic Goods Administration. COVID-19 vaccine: Provisional registrations. 2021.
   Google Scholar
• Solforosi L, Kuipers H, Jongeneelen M, Rosendahl Huber SK, van der Lubbe JEM, Dekking L, Czapska-Casey DN, Izquierdo Gil A, Baert MRM, Drijver J, et al. Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP. J Exp Med. 2021;218:e20202756. doi:10.1084/jem.20202756.
   PubMed Web of Science ®Google Scholar
• Liu AY. How important is the second dose of the COVID-19 mRNA vaccine? J Allergy Clin Immunol Pract. 2021;9:2537. doi:10.1016/j.jaip.2021.02.061.
   PubMed Web of Science ®Google Scholar
• Priyanka CO, Singh I. Protective immunity against COVID-19: Unravelling the evidences for humoral vs. cellular components. Travel Med Infect Dis. 2021;39:101911. doi:10.1016/j.tmaid.2020.101911.
   PubMed Web of Science ®Google Scholar
• Pegu A, O’-Connell S, Schmidt SD, O’-Dell S, Talana CA, Lai L, et al. Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants. bioRxiv 2021.
   Google Scholar
• Callaway E, Ledford H. How to redesign COVID vaccines so they protect against variants. Nature. 2021;590:15–16. doi:10.1038/d41586-021-00241-6.
   PubMed Web of Science ®Google Scholar
• Wu K, Choi A, Koch M, Ma L, Hill A, Nunna N, et al. Preliminary analysis of safety and immunogenicity of a SARS-CoV-2 variant vaccine booster. Medrxiv 2021.
   Google Scholar
• Lovelace JB. Pfizer CEO says third Covid vaccine dose likely needed within 12 months. Health and Science. 2021. CNBC.
   Google Scholar
• Schaefer GO, Leland RJ, Emanuel EJ. Making vaccines available to other countries before offering domestic booster vaccinations. JAMA. 2021.
   PubMed Web of Science ®Google Scholar
• Hannah Ritchie EM, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, Hasell J, Macdonald B, Beltekian D, Roser M. Coronavirus Pandemic (COVID-19). 2020.
   Google Scholar
• Choudhary OP, Choudhary P, Singh I. India’s COVID-19 vaccination drive: key challenges and resolutions. Lancet Infect Dis. 2021;21:1483–84. doi:10.1016/S1473-3099(21)00567-3.
   PubMed Web of Science ®Google Scholar
• Choudhary OP, Singh I. Making sound public health policy decisions for COVID-19 vaccination: vaccine effectiveness, safety, affordability, programmatic logistics and roll-out globally. J Travel Med. 2021. doi:10.1093/jtm/taab031.
   PubMedGoogle Scholar
• Hunziker P Impact of personalized-dose vaccination in Covid-19 with a limited vaccine supply in a 100 day period in the USA. medRxiv 2021.
   Google Scholar
• Pimenta D, Yates C, Pagel C, Gurdasani D. Delaying the second dose of covid-19 vaccines. Bmj. 2021;372:n710. doi:10.1136/bmj.n710.
   PubMedGoogle Scholar
• Acuña-Zegarra MA, Díaz-Infante S, Baca-Carrasco D, Olmos-Liceaga D. COVID-19 optimal vaccination policies: a modeling study on efficacy, natural and vaccine-induced immunity responses. Math Biosci. 2021;337:108614. doi:10.1016/j.mbs.2021.108614.
   PubMed Web of Science ®Google Scholar
• Silva PJS, Sagastizábal C, Nonato LG, Struchiner CJ, Pereira T Optimized delay of the second COVID-19 vaccine dose reduces ICU admissions. Proceedings of the National Academy of Sciences 2021; 118:e2104640118.
   Google Scholar
• Hung IFN, Poland GA. Single-Dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster. Lancet. 2021;397:854–55.
   PubMed Web of Science ®Google Scholar
• Moghadas SM, Vilches TN, Zhang K, Nourbakhsh S, Sah P, Fitzpatrick MC, Galvani AP. Evaluation of COVID-19 vaccination strategies with a delayed second dose. PLoS Biol. 2021;19:e3001211. doi:10.1371/journal.pbio.3001211.
   PubMed Web of Science ®Google Scholar
• Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Single-Dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdox1 nCov-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397:881–91. doi:10.1016/S0140-6736(21)00432-3.
   PubMed Web of Science ®Google Scholar
• Moore S, Hill EM, Dyson L, Tildesley MJ, Keeling MJ. Modelling optimal vaccination strategy for SARS-CoV-2 in the UK. PLoS Comput Biol. 2021;17:e1008849. doi:10.1371/journal.pcbi.1008849.
   PubMed Web of Science ®Google Scholar
• Rubin R. COVID-19 Vaccines vs Variants—Determining how much immunity is enough. Jama. 2021;325:1241–43. doi:10.1001/jama.2021.3370.
   PubMed Web of Science ®Google Scholar
• Bieniasz P. The case against delaying SARS-CoV-2 mRNA vaccine boosting doses. Clin Infect Dis. 2021.
   Google Scholar
• De Ponfilly GP, Pilmis B, El Kaibi I, Castreau N, Laplanche S, Le Monnier A. Is the second dose of vaccination useful in previously SARS-CoV-2-infected healthcare workers? Infect Dis Now. 2021.
   Google Scholar
• Taubel J, Spencer CS, Freier A, Camilleri D, Garitaonandia I, Lorch U. Can a second booster dose be delayed in patients who have had COVID-19? medRxiv. 2021.
   Google Scholar
• Doria-Rose N, Suthar MS, Makowski M, O’-Connell S, McDermott AB, Flach B, Ledgerwood JE, Mascola JR, Graham BS, Lin BC, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med. 2021;384:2259–61. doi:10.1056/NEJMc2103916.
   PubMed Web of Science ®Google Scholar
• Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling M-J, et al. Anti-SARS-CoV-2 antibodies persist for up to 13 months and reduce risk of reinfection. medRxiv 2021.
   Google Scholar
• Lin D, Zeng D, Gilbert P Evaluating the long-term efficacy of COVID-19 vaccines. medRxiv. 2021.
   Google Scholar
• Malek AE, Dagher H, Hachem R, Chaftari AM, Raad II. Is a single dose of mRNA vaccine sufficient for COVID‐19 survivors? J Med Virol. 2021. doi:10.1002/jmv.26915.
   PubMed Web of Science ®Google Scholar
• Pawlowski C, Lenehan P, Puranik A, Agarwal V, Venkatakrishnan AJ, Niesen MJM, et al. FDA-Authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Med (N Y) 2021.
   Google Scholar
• Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397:875–77. doi:10.1016/S0140-6736(21)00448-7.
   PubMed Web of Science ®Google Scholar
• England PH. Immunisation against infectious disease. In: Ramsay M, editor. COVID-19: the green book: Public Health England. 2021. p. 1–29.
   Google Scholar
• Cavaleri M, Enzmann H, Straus S, Cooke E. The European Medicines Agency’s EU conditional marketing authorisations for COVID-19 vaccines. Lancet. 2021;397:355–57. doi:10.1016/S0140-6736(21)00085-4.
   PubMed Web of Science ®Google Scholar
• Bernal JL, Andrews N, Gower C, Stowe J, Robertson C, Tessier E, et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdox1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. MedRxiv. 2021.
   Google Scholar
• Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, Bedston S, Beggs J, Bradley D, Chuter A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397:1646–57. doi:10.1016/S0140-6736(21)00677-2.
   PubMed Web of Science ®Google Scholar
• Jones NK, Rivett L, Seaman S, Samworth RJ, Warne B, Workman C, et al. Single-Dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. Elife. 2021;10:e68808. doi:10.7554/eLife.68808.
   PubMed Web of Science ®Google Scholar
• Mahase E. Covid-19: Order to reschedule and delay second vaccine dose is “totally unfair,” says BMA. Bmj. 2020;371:m4978. doi:10.1136/bmj.m4978.
   PubMedGoogle Scholar
• Shrestha NK, Burke PC, Nowacki AS, Terpeluk P, Gordon SM Necessity of COVID-19 vaccination in previously infected individuals. medRxiv 2021.
   Google Scholar
• Diaz RS, Vergara TR. The COVID-19 second wave: a perspective to be explored. Braz J Infect Dis. 2021;25:101537. doi:10.1016/j.bjid.2020.101537.
   PubMed Web of Science ®Google Scholar
• Saadat S, Rikhtegaran-Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, et al. Single dose vaccination in healthcare workers previously infected with SARS-CoV-2. MedRxiv 2021.
   Google Scholar
• Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Figueiredo JC, et al. Prior COVID-19 infection and antibody response to single versus double dose mRNA SARS-CoV-2 vaccination. medRxiv 2021.
   Google Scholar
• Samanovic MI, Cornelius AR, Gray-Gaillard SL, Allen JR, Karmacharya T, Wilson JP, et al. Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals. medRxiv 2021.
   Google Scholar
• Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. Longitudinal analysis reveals distinct antibody and memory B cell responses in SARS-CoV2 naive and recovered individuals following mRNA vaccination. medRxiv 2021.
   Google Scholar
• Levi R, Azzolini E, Pozzi C, Ubaldi L, Lagioia M, Mantovani A, et al. A cautionary note on recall vaccination in ex-COVID-19 subjects. medRxiv. 2021.
   Google Scholar
• Focosi D, Baj A, Maggi F. Is a single COVID-19 vaccine dose enough in convalescents? Human Vaccines Immunother. 2021;17(9):2959–61. doi:10.1080/21645515.2021.1917238.
   PubMed Web of Science ®Google Scholar
• Frieman M, Harris AD, Herati RS, Krammer F, Mantovani A, Rescigno M, et al. SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors. EBioMedicine. 2021; 68.
   PubMed Web of Science ®Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Malek JA, Ahmed AA, Mohamoud YA, Younuskunju S, et al. Assessment of the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection in an intense re-exposure setting. Clin Infect Dis. 2021;73(7): e1830–e1840. doi:10.1093/cid/ciaa1846.
   PubMed Web of Science ®Google Scholar
• Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The advisory committee on immunization practices’ interim recommendation for use of Pfizer-BioNtech COVID-19 vaccine—United States, December 2020. Morbidity Mortality Weekly Rep. 2020; 69:1922.
   Google Scholar
• Fujimoto AB, Keskinocak P, Yildirim I Significance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation. Vaccine. 2021;39(35):5055–63. doi:10.1016/j.vaccine.2021.06.067.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Balena A, Tuccinardi D, Tozzi R, Risi R, Masi D, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab Res Rev. 2022;38(1): e3465 doi:10.1002/dmrr.3465.
   PubMed Web of Science ®Google Scholar
• Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, El-Qunni AA, Haile A, Huang K, Kinnett B, Liebeskind MJ, et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv. 2021. doi:10.1101/2021.04.05.21254656.
   PubMedGoogle Scholar
• Benedict C, Cedernaes J. Could a good night’s sleep improve COVID-19 vaccine efficacy? Lancet Respir Med. 2021;9:447–48. doi:10.1016/S2213-2600(21)00126-0.
   PubMed Web of Science ®Google Scholar
• Glaser R, Kiecolt-Glaser JK, Malarkey WB, Sheridan JF. The influence of psychological stress on the immune response to vaccines. Ann N Y Acad Sci. 1998;840:649–55. doi:10.1111/j.1749-6632.1998.tb09603.x.
   PubMed Web of Science ®Google Scholar
• Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, Aye P, Navarro MJ, Lai L, Edara VV, et al. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature. 2021;594:253–58. doi:10.1038/s41586-021-03530-2.
   PubMed Web of Science ®Google Scholar
• Pearson CA, Clifford S, Pulliam JR, Eggo RM. Pre-Vaccination testing could expand coverage of two-dose COVID vaccines. Wellcome Open Res. 2021;6:105. doi:10.12688/wellcomeopenres.16835.1.
   Google Scholar
• Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, Larremore DB. Model-Informed COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021;371:916–21. doi:10.1126/science.abe6959.
   PubMed Web of Science ®Google Scholar
• Li M, Shan Y, Cai K, Ren W, Sun H, Wu S, et al. Self-Assessment of COVID-19 vaccination efficacy using a simple POCT for SARS-CoV-2 S1 protein antibody IgG-IgM. medRxiv 2021.
   Google Scholar
• Lippi G, Henry BM, Plebani M. Anti-SARS-CoV-2 antibodies testing in recipients of COVID-19 vaccination: why, when, and how? Diagnostics. 2021;11:941. doi:10.3390/diagnostics11060941.
   Web of Science ®Google Scholar
• Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, Schaefer-Babajew D, Cipolla M, Gaebler C, Lieberman JA, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592(7855):616–22. doi:10.1038/s41586-021-03324-6.
   PubMed Web of Science ®Google Scholar
• Shan D, Hsiung J, Bliden KP, Zhao S, Liao T, Wang G, et al. A new saliva-based lateral-flow SARS-CoV-2 IgG antibody test for mRNA vaccination. medRxiv 2021.
   Google Scholar
• Mahmoud SA, Ganesan S, Bissar S, Zaher W. Evaluation of serological tests for detecting SARS-CoV-2 antibodies: implementation in assessing post vaccination status. medRxiv 2021.
   Google Scholar
• Jamal SA, Pingali V, Rayapati A, Bidari V, Venkatesh V, Farooq MU, et al. A look at the usage of Antibody tests to determine level of immunity against COVID-19 after vaccination: a recent trend in India. Infect Control Hosp Epidemiol. 2021:1–6.
   Google Scholar
• Cobb BL, Sawalha AH. Detection of immunoglobulin response to COVID-19 vaccination using a novel rapid fingerstick assay. Clinical Immunology. 2021;108791. doi:10.1016/j.clim.2021.108791.
   PubMed Web of Science ®Google Scholar
• Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R, et al. Anti-Spike protein assays to determine post-vaccination antibody levels: a head-to-head comparison of five quantitative assays. MedRxiv 2021.
   Google Scholar
• Spencer AJ, McKay PF, Belij-Rammerstorfer S, Ulaszewska M, Bissett CD, Hu K, Samnuan K, Blakney AK, Wright D, Sharpe HR, et al. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nat Commun. 2021;12:2893. doi:10.1038/s41467-021-23173-1.
   PubMed Web of Science ®Google Scholar
• Wolff J, Atuire C, Bhan A, Emanuel E, Faden R, Ghimire P, Greco D, Ho CWL, Kochhar S, Moon S, et al. Ethical and policy considerations for COVID-19 vaccination modalities: delayed second dose, fractional dose, mixed vaccines. BMJ Glob Health. 2021;6:e005912. doi:10.1136/bmjgh-2021-005912.
   PubMed Web of Science ®Google Scholar